Atypical antipsychotic

Atypical antipsychotic
Drug class
Skeletal formula of clozapine, the first atypical antipsychotic (1972)
SynonymsSecond generation antipsychotic, serotonin–dopamine antagonist
Legal status
In Wikidata

Atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs (also generally known as tranquilizers and neuroleptics) used to treat psychiatric conditions. Largely introduced after the 1970s, most are approved for schizophrenia, with some having received additional approval for bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

Both typical and atypical antipsychotics are characterized by blocking receptors in the brain's dopamine pathways. Atypical antipsychotics are loosely delineated for additionally blocking activity at the 5-HT2A receptor. The utility of this classification, "atypical" vs "typical" (or "first" vs "second" generation), has been questioned, noting that each agent has its own efficacy and side-effect profile, and that this label may take away from a more nuanced view of individual properties.

Although thought to be safer than typical antipsychotics, atypical antipsychotics can still feature severe side effects, such as tardive dyskinesia, neuroleptic malignant syndrome, and metabolic issues such as weight gain and diabetes. They notably feature higher average weight gain than typical antipsychotics. Though less likely to cause extrapyramidal side effects than some potent typical antipsychotics, such as Haloperidol, only a few have shown demonstrably lower incidence than lesser-used, low-potency first-generation antipsychotics.